



Advanced Wound Therapy

Managing Superficial Wounds


Over \$25B

is spent annually on the treatment of chronic wounds.¹

6.5M people

in the U.S. suffer from deficient chronic wound healing.¹

When it comes to wound healing, good enough is never enough. Recurrence rates among those with successfully treated foot ulcers may be as high as 60%.² The management of lower extremity diabetic ulcers with advanced therapies is associated with significant reduction of major and minor amputation.³



Neox® 100 is a cryopreserved amniotic membrane allograft, ideal for shallow wounds or for larger-wound areas.

- Diabetic Foot Ulcers
- Chronic Wounds
- Dehisced Wounds
- Granulating/Epithelializing Wounds
- Hypertrophic Scars/Keloids
- Non/Minimally Exudating Wounds
- Pressure Ulcers
- Venous Ulcers
- Burns

Preserving as Much of Mother Nature as Possible

For over 36 years, our pioneering scientists have focused on understanding the regenerative features of human birth tissue—ultimately identifying HC-HA/PTX3 as a key orchestrator in human birth tissue regenerative healing.⁴⁻⁸

Our CryoTek® cryopreservation process has been shown to preserve the structural and functional integrity of the HC-HA/PTX3 complex significantly better than heat

dehydration—delivering the benefits of the natural tissue to the wound.⁹

BioTissue® Surgical human birth tissue products are aseptically processed, devascularized and cell devitalized to deliver the innate properties of human birth tissue to the wound environment.

Neox 100

Cryopreserved amniotic membrane allograft for wound applications, a thinner alternative to Neox 1K. The allograft is delivered on a non-implantable, gridded paper backing for easier handling and application.

Neox 100 Cryopreserved Amniotic Membrane Allograft	
Product Code	Size
NX-02-2020	2.0 x 2.0 cm
NX-02-3030	3.0 x 3.0 cm
NX-02-4040	4.0 x 4.0 cm
NX-02-7070	7.0 x 7.0 cm

In 7 weeks

From here...



To here.



Case and photos courtesy of Oksana Buttita, DPM PLLC, Hallandale Beach, FL.

A representative case of healing a chronic diabetic foot ulcer post transmetatarsal amputation using adjunctive Neox 100.

At 1 week, the wound was 5 x 3.5 x 0.2cm with evidence of yellow film at the distal aspect of the wound consistent with amnion dissolution.

At 7 weeks, the wound was completely epithelialized and patient discharged.

Wound Epidemiology

14.5% of Medicare beneficiaries in 2014

(8.2 million patients) were diagnosed with at least one type of wound or wound-related infection.¹⁰

Listed by prevalence:

1. Surgical wound infections **4%**
2. Diabetic wound infections **3.4%**
3. Non-healing surgical wounds **3%**

1. Swan J. *Surg Technol Int.* 2014;25:73-78.
2. Ghanassia E, Villon L, Thuan dit Dieudonne J, Boegner C, Avignon A, Sultan A. (2008). *Diab Care.* 31:1288-1292.
3. Armstrong DG, Tettelbach WH, Chang TJ, et al. *J Wound Care.* 2021 Jul 1;30(Sup7):S5-S16. doi: 10.12968/jowc.2021.30.Sup7.S5. PMID: 34256590.
4. Tseng SC. *Invest Ophthalmol Vis Sci.* 2016;57(5):ORSFh1-ORSFh8.
5. He H, Li W, Tseng DY, et al. *J Biol Chem.* 2009;284:20136-46.

6. He H, Zhang S, Tighe S, Son J, Tseng SC. *J Biol Chem.* 2013;288:25792-803.
7. Zhang S, He H, Day AJ, et al. *J Biol Chem.* 2012;287:12433-44.
8. Zhang S, Zhu YT, Chen SY, et al. *J Biol Chem.* 2014;289:13531-42.
9. Cooke M, Tan EK, Mandrycky C, He H, O'Connell J, Tseng SC. *J Wound Care.* 2014;23(10):465-476.
10. Rankin TM, Miller JD, Gruessner AC, Nickerson DS. *J Diabetes Sci Technol* 2015; 9(4): 873-880. <https://doi.org/10.1177/1932296815584796>

www.biotissue.com/surgical
7300 Corporate Drive, Suite 700, Miami, FL 33126 | 888.296.8858
© 2022 BioTissue, Inc. All rights reserved | US-NX-2200003



Clarix, Neox, CryoTek, and BioTissue are registered trademarks of TissueTech, Inc. All other trademarks used herein are proprietary to their respective owners. AmnioX Medical, Inc.'s products are now part of the BioTissue Surgical brand.

BioTissue Surgical products are authorized under the regulations of the U.S. Food and Drug Administration (FDA) governing the manufacture and distribution of Human Tissue Products. They are marketed as structural tissue products for homologous use and are used by physicians as barriers, wound coverings, conduits, and/or cushions in the treatment of their patients.